Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

310
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
310
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

205
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
205
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement From the American Heart Association.

Circulation·2026
Same author

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same author

New and emerging treatments for PBC-related pruritus.

Drugs in context·2026
Same author

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same author

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Journal of the American College of Cardiology·2026
Same author

Emerging concepts in HIV pre-exposure prophylaxis: focus on twice-yearly lenacapavir.

Drugs in context·2026

Related Experiment Video

Updated: Jul 17, 2025

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.9K

Tirzepatide for type 2 diabetes.

Sarah L Anderson1, Joel C Marrs2

  • 1Clinical Care Options, Reston, VA, USA.

Drugs in Context
|September 4, 2023
PubMed
Summary
This summary is machine-generated.

Tirzepatide, a dual GIP/GLP1RA, significantly improves glycemic control and promotes weight loss in type 2 diabetes (T2D) patients. It offers a new treatment option for those struggling to meet their T2D management goals.

Keywords:
diabetes mellitusglucagon-like peptide 1 receptor agonistglucose-dependent insulinotropic polypeptidetirzepatidetype 2 diabetes

More Related Videos

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

9.5K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.3K

Related Experiment Videos

Last Updated: Jul 17, 2025

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.9K
Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

9.5K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.3K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes (T2D) affects 95% of adults with diabetes globally, posing significant management challenges.
  • Current treatments, including GLP1RA and SGLT2i, have advanced T2D care but sustained glycemic control remains difficult.
  • Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP)/GLP1 receptor agonist (GLP1RA), offers a new therapeutic approach.

Purpose of the Study:

  • To review the glycaemic efficacy, safety, and weight loss outcomes of tirzepatide in T2D management.
  • To discuss tirzepatide's role as a first-in-class agent for T2D treatment.
  • To evaluate tirzepatide's comparative effectiveness against existing therapies.

Main Methods:

  • A narrative review of five published clinical trials (n=6278) within the SURPASS clinical trial program.
  • Analysis of data focusing on glycosylated hemoglobin (HbA1c) levels and body weight changes.
  • Assessment of adverse events reported with tirzepatide use.

Main Results:

  • Tirzepatide demonstrated significant HbA1c reductions (-1.24% to -2.11% vs. placebo; -0.6% to -1.14% vs. active comparator).
  • Substantial weight loss was observed (up to 15.5 kg vs. placebo or active comparator).
  • Tirzepatide showed superior glycaemic control and weight loss compared to a GLP1RA, with predominantly gastrointestinal adverse events.

Conclusions:

  • Tirzepatide is a highly effective first-in-class agent for improving glycaemic control and promoting weight loss in T2D.
  • It represents a promising new therapeutic option for patients with T2D who have unmet glycemic and weight management needs.
  • Ongoing cardiovascular outcomes trials (SURPASS-CVOT) will provide further insights into its safety profile.